General Information of Drug (ID: DMLYIPA)

Drug Name
SGT-53 Drug Info
Synonyms P53 gene stimulator (solid tumor), Synergene Therapeutics
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 2 [1]
Recurrent glioblastoma 2A00.00 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Cross-matching ID
TTD Drug ID
DMLYIPA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Contusugene ladenovec DMN9ETB Oral cancer 2B6E Phase 3 [5]
QPI-1002 DMDU5Y2 Renal transplantation NE84 Phase 3 [6]
Thymoquinone DMVDTR2 Polycystic ovarian syndrome 5A80.1 Phase 2/3 [7]
APG-115 DMIFA0L Prolymphocytic leukaemia 2A82.1 Phase 2 [1]
APR-246 DMNFADH Ovarian cancer 2C73 Phase 2 [8]
Ad-p53 DMJSWXL Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
Kevetrin DMFO6MH Ovarian cancer 2C73 Phase 2 [1]
INGN-225 DMF7J6D Head and neck cancer 2D42 Phase 2 [10]
ALT-801 DM9KL7P Acute myeloid leukaemia 2A60 Phase 2 [11]
ISA-P53-01 DMQ5EYJ Colorectal cancer 2B91.Z Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cellular tumor antigen p53 (TP53) TT7SBF5 P53_HUMAN Stimulator [4]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02340156) Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02354547) A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors. U.S. National Institutes of Health.
4 Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8.
5 A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
8 APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881.
9 Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38.
10 INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91.
11 Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
12 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.